Contributions
Abstract: P1281
Type: Poster Sessions
Abstract Category: Therapy - Others
Background: Diagnosis of multiple sclerosis (MS) affects mostly women in a childbearing age. Even with the indication that MS itself does not adversely affect pregnancy outcomes, MS patients have many pregnancy-related concerns regarding the use of disease-modifying therapies (DMTs). The goal of this retrospective analysis was to evaluate the onset of pregnancy for patients exposed to delayed-release dimethyl fumarate (DMF) or peginterferon beta-1a (PEG) patients, in addition to analysing obstetrical outcomes after end of pregnancy.
Methods: From February 2014 and September 2014 patients were recruited for a patient support program for DMF and PEG, respectively. All patients signed a written consent form. Contents and coaching frequency for the DMTs were adapted according to patient needs. A pregnancy form was completed upon patients' report of pregnancy and data from births and infants was collected after the expected date of the pregnancy outcome. Pregnancy forms and data of births until first of January 2018 were analysed.
Results: As of April 2018, 259 DMF-exposed pregnancies and 198 PEG-exposed pregnancies were reported. As soon as pregnancy was confirmed, the DMT was stopped for the expectant mother. For 7 and 8 cases, the expectant father was using DMF and PEG, respectively. The median age at time of reported pregnancy for the expectant mother was 31.4 years. For half of all patients it was their first pregnancy. Data on 205 and 145 pregnancy outcomes was collected for DMF and PEG, respectively. Regarding DMF 83% of the MS patients gave birth to a live and healthy infant, 1% had live births with abnormalities, 9% spontaneous abortions, 4% voluntary abortions, 2.5% premature deliveries and 0.5% foetal deaths. For PEG pregnancies, there were 74.3% live and healthy births, 0.7% live births with abnormalities, 13.6% spontaneous abortions, 6.4% voluntary abortions, 3.6% were premature deliveries and 1.4% foetal deaths. Overall, 49% and 45% of the infants were females for DMF and PEG, respectively. Most of the MS patients breastfed for more than 1 month.
Conclusion: The percentage of spontaneous abortions for MS patients exposed to DMF or PEG were in the normal range compared to the overall population. The sex distribution was also in the normal range as reported by the German birth register. DMF and PEG as disease-modifying therapies prior to and in early pregnancy appear to have no influence on the onset and outcome of pregnancies.
Disclosure: YBN, SHE: received funding for medical writing.
GN, MTG, HR, and RS: employees of and hold stock/stock options in Biogen.
Abstract: P1281
Type: Poster Sessions
Abstract Category: Therapy - Others
Background: Diagnosis of multiple sclerosis (MS) affects mostly women in a childbearing age. Even with the indication that MS itself does not adversely affect pregnancy outcomes, MS patients have many pregnancy-related concerns regarding the use of disease-modifying therapies (DMTs). The goal of this retrospective analysis was to evaluate the onset of pregnancy for patients exposed to delayed-release dimethyl fumarate (DMF) or peginterferon beta-1a (PEG) patients, in addition to analysing obstetrical outcomes after end of pregnancy.
Methods: From February 2014 and September 2014 patients were recruited for a patient support program for DMF and PEG, respectively. All patients signed a written consent form. Contents and coaching frequency for the DMTs were adapted according to patient needs. A pregnancy form was completed upon patients' report of pregnancy and data from births and infants was collected after the expected date of the pregnancy outcome. Pregnancy forms and data of births until first of January 2018 were analysed.
Results: As of April 2018, 259 DMF-exposed pregnancies and 198 PEG-exposed pregnancies were reported. As soon as pregnancy was confirmed, the DMT was stopped for the expectant mother. For 7 and 8 cases, the expectant father was using DMF and PEG, respectively. The median age at time of reported pregnancy for the expectant mother was 31.4 years. For half of all patients it was their first pregnancy. Data on 205 and 145 pregnancy outcomes was collected for DMF and PEG, respectively. Regarding DMF 83% of the MS patients gave birth to a live and healthy infant, 1% had live births with abnormalities, 9% spontaneous abortions, 4% voluntary abortions, 2.5% premature deliveries and 0.5% foetal deaths. For PEG pregnancies, there were 74.3% live and healthy births, 0.7% live births with abnormalities, 13.6% spontaneous abortions, 6.4% voluntary abortions, 3.6% were premature deliveries and 1.4% foetal deaths. Overall, 49% and 45% of the infants were females for DMF and PEG, respectively. Most of the MS patients breastfed for more than 1 month.
Conclusion: The percentage of spontaneous abortions for MS patients exposed to DMF or PEG were in the normal range compared to the overall population. The sex distribution was also in the normal range as reported by the German birth register. DMF and PEG as disease-modifying therapies prior to and in early pregnancy appear to have no influence on the onset and outcome of pregnancies.
Disclosure: YBN, SHE: received funding for medical writing.
GN, MTG, HR, and RS: employees of and hold stock/stock options in Biogen.